Osaic Holdings
HCWB icon

Osaic Holdings’s HCW Biologics HCWB Stock Holding History

Osaic Holdings’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9 Hold
4
– – ﹤0.01% 7746
2025
Q4 		$25 Hold
4
– – ﹤0.01% 7728
2025
Q3 		$96 Hold
4
– – ﹤0.01% 7748
2025
Q2 		$103 Hold
4
– – ﹤0.01% 7564
2025
Q1 		$285 Buy
+4
New +$352 ﹤0.01% 7112

Other funds holding HCWB

HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings's HCWB Position: Q1 2026 in Review

Osaic Holdings held its HCW Biologics (HCWB) position steady in Q1 2026 at 4 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #7746.

Osaic Holdings first reported a position in HCWB in Q1 2025 and has held it in 5 quarters since. The position peaked at $285 in Q1 2025. 13 funds tracked by Wall St. Rank hold HCWB as of Q1 2026.

  • Osaic Holdings held 4 shares of HCW Biologics worth $9 as of Q1 2026.
  • Osaic Holdings left its HCW Biologics share count unchanged in Q1 2026.
  • HCW Biologics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #7746 holding.
  • Osaic Holdings first reported a position in HCW Biologics in Q1 2025 and has held it in 5 quarters since.
  • Osaic Holdings's HCW Biologics position peaked at $285 in Q1 2025.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.